JP2021525512A5 - - Google Patents

Info

Publication number
JP2021525512A5
JP2021525512A5 JP2020566267A JP2020566267A JP2021525512A5 JP 2021525512 A5 JP2021525512 A5 JP 2021525512A5 JP 2020566267 A JP2020566267 A JP 2020566267A JP 2020566267 A JP2020566267 A JP 2020566267A JP 2021525512 A5 JP2021525512 A5 JP 2021525512A5
Authority
JP
Japan
Prior art keywords
sequence
seq
cdr2
cdr3
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525512A (ja
JP7210612B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034259 external-priority patent/WO2019231957A1/en
Publication of JP2021525512A publication Critical patent/JP2021525512A/ja
Publication of JP2021525512A5 publication Critical patent/JP2021525512A5/ja
Application granted granted Critical
Publication of JP7210612B2 publication Critical patent/JP7210612B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566267A 2018-05-30 2019-05-29 抗aベータ抗体及びその使用 Active JP7210612B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862678080P 2018-05-30 2018-05-30
US62/678,080 2018-05-30
PCT/US2019/034259 WO2019231957A1 (en) 2018-05-30 2019-05-29 Anti-abeta antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2021525512A JP2021525512A (ja) 2021-09-27
JP2021525512A5 true JP2021525512A5 (cg-RX-API-DMAC7.html) 2022-05-20
JP7210612B2 JP7210612B2 (ja) 2023-01-23

Family

ID=68694402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566267A Active JP7210612B2 (ja) 2018-05-30 2019-05-29 抗aベータ抗体及びその使用

Country Status (8)

Country Link
US (1) US11084873B2 (cg-RX-API-DMAC7.html)
EP (1) EP3801618A4 (cg-RX-API-DMAC7.html)
JP (1) JP7210612B2 (cg-RX-API-DMAC7.html)
KR (1) KR102523019B1 (cg-RX-API-DMAC7.html)
CN (1) CN112601550B (cg-RX-API-DMAC7.html)
CA (1) CA3100896C (cg-RX-API-DMAC7.html)
TW (1) TWI721440B (cg-RX-API-DMAC7.html)
WO (1) WO2019231957A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
CN101325972B (zh) * 2005-12-12 2020-06-16 Ac免疫有限公司 具有治疗性质的Aβ1-42特异性单克隆抗体
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
CN104109208A (zh) * 2007-11-14 2014-10-22 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
AU2008322523B2 (en) * 2007-11-16 2013-10-10 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
EP2928494A4 (en) 2012-12-07 2016-11-02 Biogen Internat Neuroscience Gmbh METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES
US9879076B2 (en) * 2013-03-15 2018-01-30 Ramot At Tel Aviv University Ltd. Methods and compositions with immune therapy for treatment of dementia
MX378944B (es) * 2014-04-18 2025-03-10 Univ New York State Res Found Anticuerpos de antígeno anti-tf humanizado.
CA3004482A1 (en) * 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
PL3430397T3 (pl) * 2016-03-14 2022-04-04 Biogen International Neuroscience Gmbh Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek

Similar Documents

Publication Publication Date Title
JP7235256B2 (ja) 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途
JP2021531254A5 (cg-RX-API-DMAC7.html)
RU2430112C2 (ru) Композиции и способы диагностики и лечения опухоли
JP2020500003A5 (cg-RX-API-DMAC7.html)
RU2019118359A (ru) Антитело к cd73 человека
JP2017205118A5 (cg-RX-API-DMAC7.html)
IL266893A (en) Meditopes and meditope-binding antibodies and uses thereof
JP2012518425A5 (cg-RX-API-DMAC7.html)
JP2021500916A5 (cg-RX-API-DMAC7.html)
HRP20201345T1 (hr) Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba
JP2018535650A5 (cg-RX-API-DMAC7.html)
JP2009517057A5 (cg-RX-API-DMAC7.html)
RU2012112829A (ru) Анти-gitr-антитела
JP2018527919A5 (cg-RX-API-DMAC7.html)
JP2016516400A5 (cg-RX-API-DMAC7.html)
JP2017507131A5 (cg-RX-API-DMAC7.html)
JP2014528695A5 (cg-RX-API-DMAC7.html)
RU2014101707A (ru) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
JP2020534830A5 (cg-RX-API-DMAC7.html)
JP2013500941A5 (cg-RX-API-DMAC7.html)
JP2014511179A5 (cg-RX-API-DMAC7.html)
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
JP2009541204A5 (cg-RX-API-DMAC7.html)
CN102686609A (zh) 修饰的可变域分子及其生产和使用方法
JP2005528914A5 (cg-RX-API-DMAC7.html)